{"id":"NCT01617434","sponsor":"Novo Nordisk A/S","briefTitle":"The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes","officialTitle":"The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2012-06-12","resultsPosted":"2014-10-28","lastUpdate":"2017-03-08"},"enrollment":451,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Liraglutide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes.","primaryOutcome":{"measure":"Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26","timeFrame":"Week 0 to Week 26","effectByArm":[{"arm":"Liraglutide","deltaMin":-1.3,"sd":1.015},{"arm":"Placebo","deltaMin":-0.11,"sd":1.088}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":86,"countries":["United States","Argentina","Canada","Finland","Germany","India","Mexico","Netherlands","Serbia"]},"refs":{"pmids":["26179619","26582052"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":225},"commonTop":["Nausea","Diarrhoea","Nasopharyngitis","Decreased appetite","Influenza"]}}